Vaccine Temporary Medical Exemption Clinical Criteria, Clinical Guidance and Resources

New Zealand COVID-19 Vaccine and Immunisation Programme

Version 1.2

MINISTRY OF HEALTH MANATŪ HAUORA

CT 1981

New Zealand Government

Table of Contents

Principles of Temporary Medical Exemption	dical exemption duration dical exemption duration ditional Support istry of Health Application /ID-19 Vaccine Temporary Medical Exemption	108 ¹
Medical exemption duration	dical exemption duration ditional Support iistry of Health Application /ID-19 Vaccine Temporary Medical Exemption	
Additional Support	litional Support istry of Health Application /ID-19 Vaccine Temporary Medical Exemption	0.96 L
Ministry of Health Application	istry of Health Application /ID-19 Vaccine Temporary Medical Exemption	
Ministry of Health Application	istry of Health Application /ID-19 Vaccine Temporary Medical Exemption	
COVID-19 Vaccine Temporary Medical Exemption	/ID-19 Vaccine Temporary Medical Exemption	
Ministry of Health Approval Record		1
UNDER THE OFFICIAL INFORM	iistry of Health Approval Record	
	ELEASED UNDER THE OFFICIAL	

Principles of Temporary Medical Exemption

- There are very few situations where a vaccine is contraindicated and, as such, a medical exemption is expected to be rarely required.
- Exemptions should be limited to situations where a suitable alternative COVID-19 vaccine is not readily available for the individual.
- Exemptions should be for a specified time, reflecting, for example, recovery from clinical conditions or the availability of alternate vaccines.
- Vaccination should be completed as soon as clinically safe within the exemption timeframe. This is particularly relevant for criteria 1C where it is unlikely that a full six months is required.
- It is likely that most people who are not medically exempt can be safely vaccinated, with some requiring extra precautions.
- The practitioner completing the application form should have an existing clinical relationship with the consumer and will support them for completing their vaccinations going forward.

Those not medically exempt

- People who had an otherwise negative experience that is not mentioned above, with other vaccines in the past.
- Disabled people once adequate resources are available to support safe delivery. People with disabilities are generally at higher risk from COVID-19, and therefore are a priority for vaccination.
- Pregnant people. Pregnancy is not a valid reason for exemption in the absence of any of the criteria listed in the above table. Pregnancy is associated with higher risk from COVID-19 compared to the general population and therefore this group are a priority for vaccination.
- A vaccination may reasonably be deferred for individuals with some acute major medical conditions, such undergoing major surgery or hospital admission for a serious illness.

Medical exemption duration

The medical exemption duration is 6 months, with the ability to apply for a new exemption if required. This time period will allow individuals who can safely be vaccinated, with either the same vaccine or an alternative vaccine, as appropriate, to be protected against COVID-19 in a timely way.

	Criteria for Temporary COVID-19 Vaccine Medical Exemptions						
Step Vaccine		Category	Criteria Details	Select Criteria Present	Supporting Evidence	Select Exemption Categories	
1	All COVID- 19 Vaccines	1A. COVID-19 Infection	 PCR-confirmed SARS-CoV-2 infection until complete recovery from the acute illness. Note: Chronic symptoms following COVID-19 ("Long COVID") is not a contraindication to COVID-19 vaccine but does warrant a clinical discussion with the patient regarding the benefits and risks. 		PCR result Letter of support from their general practitioner/nurse practitioner	1A 🗆	
		1B. Serious Adverse Event to previous dose	 Serious adverse event attributed to a previous dose of the same COVID-19 vaccine with no other cause identified. An adverse event is considered serious for the purposes of these criteria if it: 		Discharge summary Letter of support from the medical specialist within the relevant		
		FLEA	 Requires in-patient hospitalisation or prolongation of existing hospitalisation OR results in persistent or significant disability/ incapacity. AND Has been reported to CARM. AND 		scope practice		

			 Has been determined following review by, and/or on the opinion of, a relevant medical specialist to be associated with a risk of recurrence of the serious adverse event if another dose of the same vaccine is given. 	982 1	1B. □ (4 of 4 criteria required)
			Examples of serious AEFIs may include but are not limited to a immune thrombocytopenia purpura (ITP), myocarditis, potentia anaphylaxis), severe ME/CFS, or persistent or significant disabili These reactions do not include common expected local or syste within the first few days after vaccination.	illy life-threatening e ty (eg, Guillain-Barre	events (eg, e Syndrome).
		1C. Unable to tolerate administration due to risk to self or others.	• Unable to tolerate vaccine administration with resulting risk to themselves or others (eg, due to severe neurodevelopmental condition such as autistic spectrum disorder).	Letter of support from a medical specialist within the relevant scope practice	1C. 🗆
2	Pfizer Vaccine	2A. Anaphylaxis	 Anaphylaxis to the first dose of the vaccine or known severe allergy to the excipients of the vaccine as per the datasheet provided to Medsafe. This criterion will be removed as an exemption when there is an alternative vaccine available in New Zealand. 	Discharge summary Letter of support from a medical specialist within	2A. 🗆

			Many of these individuals will be able to be safely vaccinated in a controlled environment, and we recommend clinical immunologist/specialist assessment.	the relevant scope practice	
		2B. Myocarditis / Pericarditis	Myocarditis/pericarditis following the first dose of the vaccine.		2B.□
		2C. Inflammatory Cardiac Illness	Inflammatory cardiac illness within the past 6 months including: acute myocarditis, pericarditis, endocarditis, acute rheumatic fever or acute rheumatic heart disease (ie, with active myocardial inflammation).		2C.□
		2D. Acute Decompensated Heart Failure	 Acute decompensated heart failure. Although myocarditis and/or pericarditis is very rare following vaccination, if such an event were to occur, then it may exacerbate a patient's pre-existing heart failure. 		2D. 🗆
3	Trial Vaccine	3A. Non-Placebo participant in a vaccine trial	• Those who are confirmed as having the vaccine (ie, non- placebo) in any COVID-19 vaccine trial in Aotearoa New Zealand (for example, the Valneva COVID-19 vaccine trial NCT04956224).	Letter of confirmation from the Vaccine Trial Clinical Lead	3A. 🗆
		office of the second se			

Other adverse events that have been reported to the Centre for Adverse Reactions Monitoring (CARM), the Immunisation Advisory Centre (IMAC), or have been observed internationally include shingles, appendicitis, lymphadenopathy with or without fever, exacerbation of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), regional pain syndrome, and neurological events with localised arm pain. These events *may or may not* be related to the vaccine and it is generally advised to defer the second dose until the symptoms have fully resolved.

Additional Support

If you or your patient are uncertain about the criteria, please consider contacting IMAC for clinical decision-making support on **0800 IMMUNE (466 863)**.

PELEASED UNDER THE OFFICIAL INFORM



Ministry of Health Application

COVID-19 Vaccine Temporary Medical Exemption

Please send the completed application to temporarymedicalexemption@health.govt.nz

Consumer Details					
Full Name					
Contact Phone					2
Contact Address					90.
Contact Email				<u>(</u>	•
Address				A,	
Vaccine Order Status	Yes 🗆 🛛 o	r No 🗆	Date o	of Birth	
NHI					
1[], со	nsumer, cer	tify that the info	ormation I
have provided to the p	ractitioner fo	or the purposes o	of making th	nis application i	s true.
Consumer Signature		AN	14	Date Signed	
Applicant Details		- A			
Full Name		<u> </u>			
Contact Phone		\checkmark			
Contact Email					
Clinic Address					
Registration number					
Health Practitioner Index Number					
Category	□ 1A		□ 2A	□ 2C	□ 3A
exemption criteria (please tick those that apply)	□ 1B (4 of 4 □ 1C	criteria required)	□ 2B	□ 2D	
The duration of the clin	nical relations	ship with the co	nsumer is	years	months
1[] nurse	practitioner/me	dical practit	tioner [select] ce	ertify that I:
Have reviewed the cons		-			Yes / No
Have clinical evidence s exemption criteria.	upporting the	e person meets	the specifie	d COVID-19 vac	cination Yes / No

The attached supporti	ng clinical evidence is:					
			2			
			1984			
			, C			
			N N			
		ATIO				
		2Mr				
		KO,				
	workork					
	ALC: NO DECEMBER OF A					
	A					
	DE					
	ST.					
SEV						
EAS						
REFERSED						
I certify that I provide	I certify that I provide this information believing it to be true.					
Applicant Signature		Date				
		Signed				



COVID-19 Vaccine Temporary Medical Exemption

Ministry of Health Approval Record

Consumer Details					. Sol
Full Name					
Contact phone				A	
Contact email				4	
Contact Address					
Vaccine Order Status	Yes 🗆 or	No 🗆	Alle		
NHI					
Exemption start date					
Exemption expiry date					
Category exemption	□ 1A	CIA	□ 2A I	2 C	□ 3A
categories	🗆 1B	X	□ 2B] 2D	
	□ 1C				
Name	R.		Role		
Signature	NOV		Date Signed		



COVID-19 Vaccine Temporary Medical Exemption Certificate

PRIVATE AND CONFIDENTIAL

DATE: [insert date]

Re: VACCINE TEMPORARY MEDICAL EXEMPTION

This letter certifies that [full name of person being assessed] application has been assessed in accordance with the Ministry of Health's Temporary Medical Exemption Process and a temporary medical exemption has been granted.

This exemption is granted pursuant to clause 9B of the COVID-19 Public Health Response (Vaccinations) Order 2021.

This exemption expires after [*insert number*] months after the date of issue being [*insert date*].

This temporary medical exemption certificate is a recorded as [insert number].

[Ministry of Health]